Lirafugratinib Hydrochloride Patent Expiration

Lirafugratinib Hydrochloride was first introduced by Elevar Therapeutics Inc in its drug Lyrfigtu on Sep 23, 2026.


Lirafugratinib Hydrochloride Patents

Given below is the list of patents protecting Lirafugratinib Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Filter patents by

NEW
Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Lyrfigtu US12152034 Fgfr Inhibitors And Methods Of Making And Using The Same Nov 18, 2041 Elevar
Lyrfigtu US11780845 Fgfr Inhibitors And Methods Of Use Thereof May 12, 2040 Elevar



Lirafugratinib Hydrochloride's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Lirafugratinib Hydrochloride Generic API Manufacturers

Given below is the list of companies who have filed for Lirafugratinib Hydrochloride generic, along with the locations of their manufacturing plants worldwide.